Outcomes of Focal Ablation for Prostate Cancer

Recruiting now

Conditions studied: Prostate Cancer

In brief

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

Key facts

Study ID

NCT05478694

Run by

University of Texas Southwestern Medical Center

People needed

225

Starts

2023-02-01

Expected to finish

2026-08-01

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older, up to 90. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy
• Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease
• Age 18-90 years.
• Life expectancy > 1 year
• Ability to understand and the willingness to sign a written informed consent.

You may not qualify if…

• Anatomic abnormalities that do not allow for focal ablation
• Evidence of non-organ confined disease that is not feasible for ablation
• Has active urinary traction infection

Where it is running

• UTSW — Dallas, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.